Immunotherapy of human ovarian carcinoma with OVAREX(TM) MAb-B43.13 in a human-PBL-SCID/BG mouse model

Hybridoma

Volumn 18, Issue 1, 1999, Pages 47-55

  Schultes, Birgit C ^a,b   Zhang, Chengsheng ^a   Xue, Lanny Y ^a   Noujaim, Antoine A ^a   Madiyalakan, Ragupathi ^a  

^a AltaRex Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; HUMAN IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B 43 13; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ASCITES; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; CANCER SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALIA; FALLOPIA;

EID: 0032999879     PISSN: 0272457X     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.1999.18.47     Document Type: Conference Paper

References (31)

1. Clark JI, and Weiner LM: Biological treatment of human cancer. Curr. Problems Cancer 1995;19:185-262.
2. Pressman D, and Korngold L: The in vivo localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 1953;6:619-623.
3. Pressman D, Day ED, and Blau M: The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res 1957;17:845-850.
4. Adams DO, Hall T, Steplewski Z, and Koprowski H: Tumor undergoing rejection induced by monoclonal antibodies of the IgG2a isotype containing increased numbers of macrophages activated for distinctive form of antibody dependent cytolysis. Proc Natl Acad Sci USA 1984;81:3506-3510.
5. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, and Reisfeld R: Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 1987;138:3566-3572.
6. Herlyn DM, and Koprowski H: Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 1981;27:769-774.
7. Blair AH, and Ghose TI: Linkage of cytotoxic agents to immunoglobulins. J Immunol Methods 1983;59:129-143.
8. Vitteta ES, Krolick KA, and Uhr JW: Neoplastic B cells as targets for antibody-ricin A chain immunotoxins. Immunol Rev 1982;62:159-183.
9. Goldberg EP: Targeted Drugs. Wiley Intersciences, New York, 1983.
10. Jerne NK: Towards a network theory of the immune system. Ann Immunol (Inst Pasteur) 1974;125C:373-389.
11. Herlyn D, Ross AH, Iliopoulos D, and Koprowski H: Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody CO17-1A. Eur J Immunol 1987;17:1649-1652.
12. Chatterjee MB, Foon KA, and Kohler H: Idiotype antibody immunotherapy of cancer (Review). Cancer Immunol Immunother 1994;38:75-82.
13. Rosenberg SA: Principles and applications of biological therapy. In: Cancer: Principles and Practice of oncology. DeVita VT, Jr, Hellman S, and Rosenberg SA (Eds.). J.B. Lippincott Co., Philadelphia, 1993, pp. 293-310.
14. Einhorn N, Sjovall K, Knapp RC, Schoenfeld DA, Hall H, Eklund G, Scully RE, and Zurawski VR: Specificity of serum CA125 radioimmunoassay for early detection of ovarian cancer: A prospective study. Obstet Gynecol 1992;80:14-18.
15. Noujaim AA, Baum RP, Sykes TR, Madiyalakan R, Sykes CJ, Hertel A, Niesen A, and Hör G: Monoclonal antibody B43.13 for immunoscintigraphy and immunotherapy of ovarian cancer. In: Current Tumor Diagnosis: Applications, Clinical Relevance, Trends. Klapdor R (Ed.). W Zuckschwerdt Verlag, München, 1994, pp. 823-829.
16. Jensen JL, MacLean GD, Suresh MR, Almeida A, Jette D, Lloyd S, Bodnar D, Krantz M, and Longenecker BM: Possible utility of serum determination of CA125 and CA27.29 in breast cancer management. Int J Biol Markers 1991;6:1-6.
17. Capstick V, MacLean GD, Suresh MR, Bodnar D, Lloyd S, Shepert L, Longenecker BM, and Krantz M: Clinical evaluation of a new two-site assay for CA125 antigen. Int J Biol Markers 1991;6:129-135.
18. Krantz MJ, MacLean GD, Longenecker BM, and Suresh MR: A radioimmunoassay for CA125 employing two new monoclonal antibodies. J Cell Biochem 1988;12E(Suppl.):139.
19. Baum RP, Niesen A, Hertel A, Nanci A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, and Hör G: Activating Anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian cancer. Cancer 1994;73:1121-1125.
20. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, and Noujaim AA: Anti-idiotype induction therapy: Evidence for the induction of immune response through the idiotypic network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 1995;14:199-203.
21. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, and Hör G: Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 1993;12:583-589.
22. Donnerstag B, Oltrogge JB, Baum RP, Skerlo M, Niesen A, Hor G, and Trager L: Immunological profile of patients with ovarian cancer under immunostimulation with murine monoclonal antibodies. Int J Oncol 1995;6:853-858.
23. Sykes TR, Woo TK, Baum RP, Qi P, and Noujaim AA: Direct labeling of monoclonal antibodies with technetium-99m by photoactivation. J Nucl Med 1995;36:1913-1922.
24. Hendrickson EA: The SCID mouse: Relevance as an animal model system for studying human diseases. Am J Pathol 1993;143: 1511-1522.
25. Torbett BE, Picchio G, and Mosier DE: Hu-PBL-SCID mice: A model for human immune function, AIDS, and lymphomagionesis. Immunol Rev 1991;124:139-164.
26. Malkovska V, Cigel F, and Storer BE: Human T cells in hu-PBL-SCID mice proliferate in response to Daudi lymphoma and confer anti-tumor immunity. Clin Exp Immunol 1994;96:158-165.
27. Walker W, and Gallagher G: The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice. Immunology 1994;83:163-170.
28. Sandhu J, Spitz B, Gallinger S, and Hozumi N: Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J Immunol 1994;152:3806-3813.
29. 1). Cancer Immunol Immunother 1998;46:201-212.
30. Fagerberg J, Frodin JE, Ragnhammer P, Steinitz M, Wigzell H, and Mellstedt H: Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). Cancer Immunol Immunother 1994;38:149-159.
31. Kosmas C, Epenetos AA, and Courtenay-Luck NS: Activation of Cellular Immunity after Intracavitary Monoclonal Antibody Therapy of Ovarian Cancer. Cancer 1994;73:3000-3010.